Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,243.00
Bid: 1,244.80
Ask: 1,245.80
Change: 18.80 (1.54%)
Spread: 1.00 (0.08%)
Open: 1,212.40
High: 1,247.00
Low: 1,210.80
Yest. Close: 1,224.20
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

RNS Alerts are a premium feature

Login to your account

myTerminal is a premium feature

Login to your account

Don't have an account? Click here to register.

UK study confirms GSK flu shot link to rare sleep disorder

* At least 14-fold increased narcolepsy risk after Pandemrix * Boosted vaccine may have triggered adverse immune response * GlaxoSmithKline says determined to understand more * Drugmaker has reports of almost 800 cases across Europe By Kate Kelland LONDON, Feb 27 (Re

26 Feb 13 23:30

Switzerland's Roche pledges to open up access to drug data

* Says will give third-party researchers access to trial data * Follows GSK decision to publish reports and data * Drugmakers under pressure to increase transparency ZURICH, Feb 26 (Reuters) - Swiss drugmaker Roche Holding has agreed to expand access to its clinical trial data

26 Feb 13 17:44

UPDATE 3-Dynavax may have to repitch hep B vaccine for smaller market

* Says FDA seeks more data to evaluate vaccine's safety * Says FDA willing to discuss restricted approval * Shares fall 37 pct to lowest in more than a year (Adds analysts' comments, company comments from conference call) By Zeba Siddiqui Feb 25 (Reuters) - Dynavax Techn

25 Feb 13 17:33

UPDATE 2-Dynavax slides as FDA rejects adult hep B vaccine

* Says FDA seeks more data to evaluate vaccine's safety * Says FDA willing to discuss restricted approval * Shares fall as much as 38 pct premarket By Zeba Siddiqui Feb 25 (Reuters) - U.S. health regulators denied approval for Dynavax Technologies Inc's adult hepatitis B v

25 Feb 13 13:31

UPDATE 1-FDA rejects Dynavax's adult hep B vaccine on safety concerns

* Says FDA seeks more data to evaluate vaccine's safety * Says FDA willing to discuss restricted approval Feb 25 (Reuters) - U.S. health regulators denied approval for Dynavax Technologies Inc's adult hepatitis B vaccine pending additional data to evaluate its safety, potentially dela

25 Feb 13 11:52

FDA rejects Dynavax's adult hep B vaccine on safety concerns

Feb 25 (Reuters) - U.S. health regulators denied approval to Dynavax Technologies Inc's adult hepatitis B vaccine in its current form and asked for more data to evaluate the vaccine's safety. The U.S. Food and Drug Administration indicated it was willing to have discussions for a more restr

25 Feb 13 11:10

Friday broker round-up UPDATE

Antofagasta: RBC upgrades from underperform to outperform. Ashmore Group: Citigroup raises target price from 330p to 355p upgrading to neutral. JP Morgan ups target price from 361p to 413p and maintains a neutral rating. Babcock International: Citigroup revises target price from 965p to 1185p and

22 Feb 13 07:12

UPDATE 1-In U.S., flu vaccine worked in just over half of those who got it

* Protection even lower among people 65 and older * Officials say findings underscore need for better vaccines By Julie Steenhuysen CHICAGO, Feb 21 (Reuters) - A U.S. government analysis of this season's flu vaccine suggests it was effective in only 56 percent of people who got

21 Feb 13 22:49

Flu vaccine worked in just over half of Americans who got it

* Failed to protect elderly against one strain of flu * Officials say underscores the need for better flu vaccines By Julie Steenhuysen CHICAGO, Feb 21 (Reuters) - A U.S. government analysis of this season's flu vaccine suggests it was effective in only 56 percent of people who

21 Feb 13 18:58

Louis Freeh's law firm taps top white-collar lawyers

By Casey Sullivan NEW YORK, Feb 21 (Reuters) - Law firm Pepper Hamilton, which two weeks ago elevated former FBI director Louis Freeh to chairman, said on Thursday it had hired Larry Byrne, a former federal prosecutor and head of Linklaters' U.S. litigation department in New York, along wit

21 Feb 13 16:28

UPDATE 1-GSK wins priority status for new HIV drug in U.S.

LONDON, Feb 15 (Reuters) - U.S. regulators gave priority review status to an experimental GlaxoSmithKline drug for HIV/AIDS, which industry analysts view as a possible multibillion-dollar-a-year seller. The U.S. Food and Drug Administration awards certain drugs priority status when they hav

15 Feb 13 16:08

TEXT-Fitch:Europe woes push big pharma more towards emerging markets

Feb 14 - Reports of bid interest in Brazilian drug company Ache Laboratorios Farmaceuticos reinforce our expectation that major European pharmaceutical companies will aim for even greater emerging market diversification to boost growth, Fitch Ratings says. The shift in focus is a respons

14 Feb 13 12:35

GSK, others weigh $3-4 bln deal for Brazilian drugmaker -sources

* GSK keen to acquire privately owned Ache -sources * Novartis, Pfizer, Abbott also likely to be interested * Sale by Lazard could value firm at $3-4 bln or more * Ache owners' rift makes outcome of process uncertain By Ben Hirschler and Nadia Damouni LONDON/NEW YORK

12 Feb 13 16:32

UPDATE 4-Novo Nordisk hit hard as U.S. rebuffs insulin drug

* FDA demands new study on Tresiba's cardiovascular safety * Novo CEO "surprised and disappointed" * $2.8 bln consensus sales forecast for 2017 set to fall * Setback is positive for Sanofi's rival product Lantus * Novo shares tumble 12.5 percent, Sanofi gains 4.5 percent

11 Feb 13 13:02

UPDATE 3-Novo Nordisk hit hard as U.S. rebuffs insulin drug

* FDA demands new study on Tresiba's cardiovascular safety * Novo CEO says "surprised and disappointed" by FDA move * Setback is positive for Sanofi's rival product Lantus * Novo shares tumble 12 percent, Sanofi gains 4 percent (Adds comment from Novo chief scientist, latest s

11 Feb 13 10:44

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.